deltatrials
Completed PHASE3 NCT00003958

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma

Sponsor: Children's Oncology Group

Conditions Adult Malignant Mesenchymoma Adult Rhabdomyosarcoma Alveolar Childhood Rhabdomyosarcoma Childhood Malignant Mesenchymoma Embryonal Childhood Rhabdomyosarcoma Embryonal-botryoid Childhood Rhabdomyosarcoma Nonmetastatic Childhood Soft Tissue Sarcoma Previously Untreated Childhood Rhabdomyosarcoma Stage I Adult Soft Tissue Sarcoma Stage II Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma
Interventions cyclophosphamide dactinomycin filgrastim laboratory biomarker analysis radiation therapy sargramostim therapeutic conventional surgery topotecan hydrochloride vincristine sulfate
Updated 6 times since 2017 Last updated: Jun 13, 2013 Started: Sep 30, 2002 Primary completion: Oct 31, 2007

A PHASE3 clinical study on Adult Malignant Mesenchymoma and Adult Rhabdomyosarcoma, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Arcadia, United States